×
About 6,516 results

ALLMedicine™ Immune Thrombocytopenia Center

Research & Reviews  3,127 results

Anti-inflammatory activity of CD44 antibodies in murine immune thrombocytopenia is medi...
https://doi.org/10.1182/blood.2020009497
Blood Norris PAA, Kaur G et. al.

Mar 4th, 2021 - Monoclonal IgG antibodies to CD44 (anti-CD44) are anti-inflammatory in numerous murine autoimmune models but the mechanisms are poorly understood. Anti-CD44 anti-inflammatory activity shows complete therapeutic concordance with intravenous immunog...

Increased Expression of IL-17A and IL-17F Is Correlated With RUNX1 and RORγT in Pediatr...
https://doi.org/10.1097/MPH.0000000000002108
Journal of Pediatric Hematology/oncology; Elnaenaey WA, Omar OM et. al.

Feb 26th, 2021 - Immune thrombocytopenia (ITP) is characterized by dysregulated cellular immunity. Interleukin 17 (IL-17) and its secreting cells (Th17) are involved in the pathogenesis of ITP. Retinoic acid receptor-related orphan receptor γt (RORγt) is the chief...

A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin recept...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905908
Journal of Hematology & Oncology; Mei H, Liu X et. al.

Feb 26th, 2021 - Hetrombopag, a novel thrombopoietin receptor agonist, has been found in phase I studies to increase platelet counts and reduce bleeding risks in adults with immune thrombocytopenia (ITP). This phase III study aimed to evaluate the efficacy and saf...

Clinical spectrum, outcome and management of immune thrombocytopenia associated with my...
https://doi.org/10.3324/haematol.2020.272559
Haematologica Jachiet V, Moulis G et. al.

Feb 25th, 2021 - Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) are associated with systemic inflammatory or autoimmune diseases in 10-20 % of cases. Among them, immune thrombocytopenia (ITP) has been reported but large studies assessin...

see more →

Guidelines  13 results

American Society of Hematology 2019 guidelines for immune thrombocytopenia.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963252
Blood Advances; Neunert C, Terrell DR et. al.

Dec 3rd, 2019 - Despite an increase in the number of therapies available to treat patients with immune thrombocytopenia (ITP), there are minimal data from randomized trials to assist physicians with the management of patients. These evidence-based guidelines of t...

Dova Pharmaceuticals Announces Fda Approval Of Supplemental New Drug Application For Doptelet® (Avatrombopag) For Treatment Of Chronic Immune Thrombocytopenia (ITP)
http://investors.dova.com/news-releases/news-release-details/dova-pharmaceuticals-announces-fda-approval-supplemental-new

Jun 26th, 2019 - Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases where there is a high unmet need, today announced the U.S. Food and Drug Administration (FDA) ap...

The prevention of glucocorticoid-induced osteoporosis in patients with immune thrombocy...
https://doi.org/10.1111/bjh.15735
British Journal of Haematology; Hill QA, Grainger JD et. al.

Jan 4th, 2019 - The prevention of glucocorticoid-induced osteoporosis in patients with immune thrombocytopenia receiving steroids: a British Society for Haematology Good Practice Paper.|2019|Hill QA,Grainger JD,Thachil J,Provan D,Evans G,|adverse effects,therapeu...

Recommendations for standardization of laboratory testing for drug-induced immune throm...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854622
Journal of Thrombosis and Haemostasis : JTH; Arnold DM, Curtis BR et. al.

Jan 21st, 2015 - Recommendations for standardization of laboratory testing for drug-induced immune thrombocytopenia: communication from the SSC of the ISTH.|2015|Arnold DM,Curtis BR,Bakchoul T, ,|standards,blood,chemically induced,diagnosis,immunology,

Recommendations for the implementation of platelet autoantibody testing in clinical tri...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854629
Journal of Thrombosis and Haemostasis : JTH; Arnold DM, Santoso S et. al.

Feb 15th, 2012 - Recommendations for the implementation of platelet autoantibody testing in clinical trials of immune thrombocytopenia.|2012|Arnold DM,Santoso S,Greinacher A, ,|blood,immunology,methods,standards,immunology,immunology,immunology,immunology,

see more →

Drugs  19 results see all →

Clinicaltrials.gov  3,209 results

Anti-inflammatory activity of CD44 antibodies in murine immune thrombocytopenia is medi...
https://doi.org/10.1182/blood.2020009497
Blood Norris PAA, Kaur G et. al.

Mar 4th, 2021 - Monoclonal IgG antibodies to CD44 (anti-CD44) are anti-inflammatory in numerous murine autoimmune models but the mechanisms are poorly understood. Anti-CD44 anti-inflammatory activity shows complete therapeutic concordance with intravenous immunog...

Increased Expression of IL-17A and IL-17F Is Correlated With RUNX1 and RORγT in Pediatr...
https://doi.org/10.1097/MPH.0000000000002108
Journal of Pediatric Hematology/oncology; Elnaenaey WA, Omar OM et. al.

Feb 26th, 2021 - Immune thrombocytopenia (ITP) is characterized by dysregulated cellular immunity. Interleukin 17 (IL-17) and its secreting cells (Th17) are involved in the pathogenesis of ITP. Retinoic acid receptor-related orphan receptor γt (RORγt) is the chief...

A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin recept...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905908
Journal of Hematology & Oncology; Mei H, Liu X et. al.

Feb 26th, 2021 - Hetrombopag, a novel thrombopoietin receptor agonist, has been found in phase I studies to increase platelet counts and reduce bleeding risks in adults with immune thrombocytopenia (ITP). This phase III study aimed to evaluate the efficacy and saf...

Clinical spectrum, outcome and management of immune thrombocytopenia associated with my...
https://doi.org/10.3324/haematol.2020.272559
Haematologica Jachiet V, Moulis G et. al.

Feb 25th, 2021 - Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) are associated with systemic inflammatory or autoimmune diseases in 10-20 % of cases. Among them, immune thrombocytopenia (ITP) has been reported but large studies assessin...

see more →

News  133 results

Mycophenolate Shows Promise in Immune Thrombocytopenia
https://www.medscape.com/viewarticle/942584

Dec 13th, 2020 - A drug currently used to prevent rejection in patients who receive solid organ transplants could have a use in the treatment of a completely different patient population ― those with immune thrombocytopenia (ITP). The drug is mycophenolate mofetil...

Mycophenolate a Potential First-line Therapy for ITP
https://www.medscape.com/viewarticle/942374

Dec 9th, 2020 - Treatment-naïve immune thrombocytopenia (ITP) patients could more than halve their risk of treatment failure with mycophenolate alongside a course of corticosteroids compared with corticosteroids alone, conclude UK researchers in the first randomi...

Falling Splenectomy Rates in ITP Raise Questions Over Role
https://www.medscape.com/viewarticle/929773

May 10th, 2020 - Patients with immune thrombocytopenia (ITP) are undergoing fewer and fewer splenectomies later and later in the disease course, which is resulting in lower gains from the procedure, say UK researchers, who question its ongoing role. The research w...

Age, sex, and other factors linked to risk of intracranial hemorrhage in ITP
https://www.mdedge.com/hematology-oncology/article/214454/bleeding-disorders/age-sex-and-other-factors-linked-risk?channel=39313
Jennifer Smith

Dec 17th, 2019 - ORLANDO – A large, retrospective study suggests several factors are associated with an increased risk of intracranial hemorrhage in patients with immune thrombocytopenia. Jennifer Smith/MDedge News Mayank Sharma Data on more than 300,000 immune th.

Phase 2 studies show potential of FcRn blockade in primary ITP
https://www.mdedge.com/hematology-oncology/article/214197/bleeding-disorders/phase-2-studies-show-potential-fcrn-blockade?channel=39313
Andrew D. Bowser

Dec 12th, 2019 - ORLANDO – Treatments targeted to the neonatal Fc receptor are showing promise in phase 2 studies in primary immune thrombocytopenia, investigators reported at the annual meeting of the American Society of Hematology. Encouraging outcomes support t.

see more →

Patient Education  15 results see all →